<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To examine whether <z:chebi fb="0" ids="49200">proton-pump inhibitor</z:chebi> (<z:chebi fb="4" ids="53266">PPI</z:chebi>) therapy influences the incidence and progression of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> in patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN AND SETTING: Review of prospective data on patients undergoing surveillance with regular endoscopy and biopsy at a private endoscopy centre in Canberra, ACT, between 1981 and 2001 </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS: 350 patients diagnosed with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>INTERVENTIONS: <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy was progressively introduced into clinical practice from late 1989 </plain></SENT>
<SENT sid="4" pm="."><plain>Once begun, <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy was ongoing, with no attempt to reduce the dose </plain></SENT>
<SENT sid="5" pm="."><plain>MAIN OUTCOME MEASURES: Relationship between development of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and delay between diagnosis with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> and starting <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy was determined by Cox regression analyses, stratified by year of enrollment </plain></SENT>
<SENT sid="6" pm="."><plain>Age, sex, presence of macroscopic markers (severe <z:e sem="disease" ids="C0014868" disease_type="Disease or Syndrome" abbrv="">oesophagitis</z:e>, nodularity, Barrett's <z:mpath ids='MPATH_579'>ulcer</z:mpath>, stricture) and use of aspirin or <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> were considered as confounding factors in the regression analyses </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: The 350 patients had 1422 surveillance endoscopies, with a median follow-up of 4.7 years </plain></SENT>
<SENT sid="8" pm="."><plain>Patients who delayed using a <z:chebi fb="4" ids="53266">PPI</z:chebi> for 2 years or more after diagnosis with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> had 5.6 times (95% CI, 2.0-15.7) the risk of developing low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> at any given time as those who used a <z:chebi fb="4" ids="53266">PPI</z:chebi> in the first year </plain></SENT>
<SENT sid="9" pm="."><plain>Similar results were found for the risk of developing high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (hazard ratio, 20.9; 95% CI, 2.8-158) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Use of ongoing <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy appeared beneficial in the prevention of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> in patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>We suggest that <z:hpo ids='HP_0000001'>all</z:hpo> patients with this condition, even those with no <z:e sem="disease" ids="C0014868" disease_type="Disease or Syndrome" abbrv="">oesophagitis</z:e> or symptoms, should be encouraged to continue long term <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy </plain></SENT>
</text></document>